|
市場調査レポート
商品コード
1261397
子宮摘出装置の世界市場規模、シェア、産業動向分析レポート疾患タイプ別、エンドユーザー別、手術アプローチ別、地域別展望と予測、2022年~2028年Global Hysterectomy Device Market Size, Share & Industry Trends Analysis Report By Disease Type, By End User, By Surgical Approach, By Regional Outlook and Forecast, 2022 - 2028 |
||||||
子宮摘出装置の世界市場規模、シェア、産業動向分析レポート疾患タイプ別、エンドユーザー別、手術アプローチ別、地域別展望と予測、2022年~2028年 |
出版日: 2023年03月31日
発行: KBV Research
ページ情報: 英文 223 Pages
納期: 即納可能
|
子宮摘出装置市場規模は、予測期間中にCAGR 5.5%の市場成長で上昇し、2028年には 4億5,050万米ドルに達すると予測されます。
女性が妊娠している間、子宮は子宮とも呼ばれ、赤ちゃんが成長する場所です。子宮は子宮部分切除術で摘出されますが、子宮頸部は残ります。子宮頸部は子宮の首の部分です。そして、子宮全摘術で子宮と子宮頸部を摘出します。さらに、膣切開で子宮摘出術を行うこともでき、これは膣式子宮摘出術と呼ばれます。また、お腹の小さな切開口から細長い器具を挿入するロボット手術や腹腔鏡手術を受けることもあります。
子宮が巨大である場合、病気の症状について他の骨盤内臓器を調べたい場合、医師が患者さんにとって最善の選択肢であると考え、開腹手術を提案する場合など、他の子宮摘出術の代わりに腹式子宮摘出術を必要とすることがあります。子宮がんや子宮頸がんは、子宮摘出が最善の治療法である場合があります。その他の治療法としては、がんの種類やステージに応じて、放射線療法や化学療法があります。
COVID-19影響度分析
COVID-19のパンデミックは、世界中のヘルスケア関係者に困難をもたらしました。その結果、COVID-19患者のケアのために、子宮マニピュレーター機器の業界を含む他のヘルスケアサービスから資源が流用されました。パンデミックの最中、多くの患者さんが婦人科手術の治療を受けるのに大幅な遅れを経験しました。製品の需要、事業、サプライチェーン、流通ネットワーク、製品の研究開発能力など、多数の事業の多くの部分がCOVID-19の大流行により影響を受けています。その結果、COVID-19は子宮摘出器具の市場に初期段階で大きな影響を与えると予想されます。
市場成長要因
肥満の増加
5歳から19歳の子供と青少年における過体重と肥満の有病率は著しく増加しており、1975年にはおよそ4%だったものが、2016年には18%強に上昇しました。2016年には1億2,400万人以上の子供とティーンが肥満であり、1975年には5歳から19歳の間で1%未満であったのが、増加しました。さらに、女性(40%)は男性(35%)よりも肥満になりやすく、女性の健康はいくつかの異なる方法で肥満によって大きく影響されます。したがって、女性の肥満の増加は、子宮筋腫、子宮がん、慢性骨盤痛などの問題を引き起こし、子宮摘出手術の必要性を高め、子宮摘出装置市場の成長を促進すると予想されます。
子宮摘出手術に使用されるデバイスの絶え間ない進歩
医学の進歩により、多くの手術の危険性が減少し、現在では低侵襲手術とみなされるようになりました。このような進歩により、子宮摘出手術を必要とする女性にとって、子宮摘出手術はこれまで以上に安全で侵襲の少ないものとなりました。ロボット手術技術の進歩により、おへそに隠れる1インチの切開で子宮摘出手術を行うことができるようになりました。単部位ロボット子宮摘出術は、低侵襲手術の利点をすべて備えており、ほとんどの場合、傷跡がまったく残らないです。
市場抑制要因
薬物療法や低侵襲手術の有無
血液の供給が絶たれると、筋腫は数週間から数ヶ月で死滅し、小さくなっていきます。この方法は、この手術後に流産やその他の妊娠の問題が発生するリスクがかなり高いことが研究で明らかになっているため、すぐに妊娠することを望まない女性に適しているかもしれません。筋腫核出術は、子宮を摘出することなく筋腫を摘出する手術で、将来の妊娠を可能にする方法です。他の子宮温存手術と同様、筋腫の再発の可能性があります。低侵襲手術、ホルモン療法、医薬品が利用可能になると、患者の好みがそちらに移り、子宮摘出装置市場の成長が制限されるかもしれません。
疾患タイプ別展望
疾患タイプに基づき、子宮摘出装置市場は、子宮がん、子宮筋腫、慢性骨盤痛、その他に区分されます。2021年の子宮摘出装置市場では、慢性骨盤痛のセグメントが最も高い収益シェアを占めています。これは、女性の骨盤における衰弱性、持続性、慢性的な不快感であるためです。慢性的な骨盤の不快感は、過敏性腸症候群、大うつ病性疾患、骨盤内炎症症候群などの併存疾患を伴うことが多いです。持続的な骨盤の不快感は、いくつかの潜在的な原因を持つ複雑な病気です。
エンドユーザーの展望
エンドユーザー別に見ると、子宮摘出装置市場は、病院、外来手術センター、その他に分けられます。外来手術センターセグメントは、2021年の子宮摘出装置市場でかなりの収益シェアを調達しました。この成長は、外来治療への高い要望、低侵襲処置の使用の増加、外来手術センターで行われる腹腔鏡処置の手頃な価格など、いくつかの要因に起因しています。低侵襲性腹腔鏡手術では術後合併症のリスクが低いため、移動式手術施設の需要が高まると予想されます。
外科的アプローチの展望
手術アプローチ別に、子宮摘出装置市場は、ロボット支援腹腔鏡下子宮摘出術、腹腔鏡下子宮摘出術、膣式子宮摘出術、腹腔鏡下子宮摘出術に分類されます。腹部子宮摘出術セグメントは、2021年の子宮摘出術デバイス市場で最も高い収益シェアを記録しました。これは、特に患者が持続的な骨盤の不快感や多量の不正出血に悩まされている場合、生活の質を向上させるなどの利点があることに起因しています。6~8インチの腹部切開により、子宮を摘出します。切開は、へそから恥骨まで、または恥骨の髪の生え際の上部に沿って行われます。
地域別展望
地域別に、子宮摘出装置市場は北米、欧州、アジア太平洋、LAMEAで分析されています。北米地域は、2021年に最大の収益シェアを獲得して、子宮摘出装置市場をリードしました。これは、同地域のいくつかの重要なプレーヤーと技術的な改善によるものです。これらの有力プレイヤーは、買収戦略において不可欠な役割を担っています。さらに、この地域の子宮がん有病率の上昇、強力な消費者基盤、消費力、確立されたヘルスケアインフラは、この地域の子宮摘出装置市場の拡大を促進すると予想されています。
The Global Hysterectomy Device Market size is expected to reach $450.5 Million by 2028, rising at a market growth of 5.5% CAGR during the forecast period.
The hysterectomy is the name for the surgical surgery used to remove a woman's uterus. Moreover, this procedure can treat various chronic pain disorders, infections, and some forms of cancer. Depending on the goal of the procedure, a hysterectomy can take various forms. The entire uterus is typically removed in these operations. Hysterectomy can be used to treat uncontrollable vaginal bleeding, persistent pelvic pain, and cancer of the uterus, cervix, or ovaries.
Fibroids, which are benign tumors growing in the uterus, and uterine prolapse, which is when the uterus protrudes from the vagina through the cervix, can also be treated with it joined with adenomyosis, which is a condition in which the lining of the uterus grows into the muscles of the uterus, and pelvic inflammatory disease. A lower belly cut, commonly known as the abdomen, is used during an abdominal hysterectomy to remove the uterus, known as an open procedure.
While a woman is pregnant, the uterus, also known as the womb, is where the baby develops. The uterus is removed with a partial hysterectomy, but the womb's neck remains. The cervix is the womb's neck. Then, the uterus and cervix are removed during a complete hysterectomy. Moreover, a vaginal incision can be used to perform a hysterectomy which is called a vaginal hysterectomy. Alternatively, one might have robotic or laparoscopic surgery, which inserts long, thin equipment through tiny belly incisions.
In place of other hysterectomy procedures, one might require an abdominal hysterectomy if: the uterus is enormous; the doctor wants to examine other pelvic organs for illness symptoms; the doctor suggests an open procedure because it might be the best option for the patient, in their opinion. A hysterectomy may be the best course of treatment for uterine or cervical cancer. Other treatment options may include radiation or chemotherapy, depending on the type of cancer and its stage.
COVID-19 Impact Analysis
The COVID-19 pandemic presented difficulties for healthcare practitioners around the world. As a result, resources were diverted from other healthcare services, including the industry for uterine manipulator devices, to care for COVID-19 patients. Many patients experienced significant delays in receiving gynecologic surgical care during the height of the pandemic. Many parts of numerous businesses, including product demand, operations, supply chains, distribution networks, and the capacity to conduct product research and development, are impacted by the COVID-19 pandemic. As a result, COVID-19 is anticipated to impact the market for hysterectomy device greatly in the initial period.
Market Growth Factors
Rising prevalence of obesity
The prevalence of overweight and obesity among children and adolescents aged 5 to 19 has significantly grown, rising from roughly 4% in 1975 to a little over 18% in 2016. More than 124 million children and teens were obese in 2016, up from less than 1% in 1975 among those aged 5 to 19. Furthermore, women (40%) are more likely to be obese than men (35%), and women's health is majorly impacted by obesity in several distinct ways. Hence, the increasing obesity in women is expected to cause issues like fibroids, uterine cancer, or chronic pelvic pain that will increase the requirement for hysterectomies and boost the hysterectomy device market growth.
The constant advancement of devices used in hysterectomy
Medical advancements have reduced the hazards of many surgeries to the point where they are now regarded as minimally invasive procedures. These developments have made hysterectomy surgery safer and less intrusive than ever for women who require this surgical removal of the uterus. A one-inch incision concealed in the belly button can now be used to perform hysterectomies due to the recent advancements in robotic surgery technology. The single-site robotic hysterectomy offers all the advantages of minimally invasive surgery and, in most cases, results in absolutely no scarring.
Market Restraining Factors
Presence of medications and minimally invasive surgeries
The fibroids die and diminish within a few weeks to months once the blood supply is severed. This method might be better suitable for women who don't want to become pregnant shortly because studies have revealed a considerable risk of miscarriage and other pregnancy issues after this operation. Myomectomy, which allows for future pregnancies, is the surgical removal of the fibroids without removing the uterus. There is a chance of fibroid recurrence, like every other uterus-sparing operation. The availability of minimally invasive procedures, hormone therapies, and medicines might shift patients' preference toward them and restrict the hysterectomy device market growth.
Disease Type Outlook
Based on disease type, the hysterectomy device market is segmented into uterine cancer, fibroids, chronic pelvic pain and others. The chronic pelvic pain segment held the highest revenue share in the hysterectomy device market in 2021. This is because it is a debilitating, persistent, chronic discomfort in a women's pelvis. Chronic pelvic discomfort is frequently accompanied by comorbidities such as irritable bowel syndrome, major depressive illness, or pelvic inflammatory syndrome. Persistent pelvic discomfort is a complicated illness with several potential causes.
End User Outlook
On the basis of end user, the hysterectomy device market is divided into hospitals, ambulatory surgical centers and others. The ambulatory surgical centers segment procured a substantial revenue share in the hysterectomy device market in 2021. The growth is attributed to several factors, including a high desire for outpatient treatments, an increase in the use of minimally invasive procedures, and the affordability of laparoscopic procedures performed in ambulatory surgery centers. The demand for mobile surgery facilities is anticipated to rise due to the lower risk of postoperative complications in minimally invasive laparoscopic surgery.
Surgical Approach Outlook
By surgical approach, the hysterectomy device market is classified into robotic assisted laparoscopic hysterectomy, abdominal hysterectomy, vaginal hysterectomy and laparoscopic hysterectomy. The abdominal hysterectomy segment registered the highest revenue share in the hysterectomy device market in 2021. This is owing to the benefits like improving the quality of life, particularly if the patient suffers from persistent pelvic discomfort or heavy, irregular bleeding. Through a six- to eight-inch abdominal incision, the uterus is removed. The incision is either done from the navel to the pubic bone or along the top of the pubic hairline.
Regional Outlook
Region-wise, the hysterectomy device market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region led the hysterectomy device market by generating the maximum revenue share in 2021. This is due to several significant players and technical improvements in the region. These leading players play an essential role in acquisition strategies. Furthermore, the region's rising uterine cancer prevalence, strong consumer base, spending power, and established healthcare infrastructure are anticipated to fuel the hysterectomy device market expansion in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, B. Braun Melsungen AG, ConMed Corporation, Johnson & Johnson, Richard Wolf GmbH, Karl Storz SE & Co. KG, The Cooper Companies, Inc., Laborie Medical Technologies (Patricia Industries) (Investor AB), Fortimedix Surgical B.V., and Conkin Surgical Instruments Ltd.
Strategies deployed in Hysterectomy Devices Market
Feb-2023: Laborie announced the acquisition of Novonate and its LifeBubble technology, a device used to raise the foetal head, making birth easier and less traumatic for the mother and baby. Together, the companies are focused on advancing the standard of care for neonates in intensive care.
Nov-2022: Medtronic Private Limited, a division of Medtronic PLC announced the launch of the TruClear system, a mechanical hysteroscopic tissue removal for efficient and safe treatment of intra-uterine anomalies (IUA). Unlike other intrauterine abnormality therapy methods, the TruClear device eliminates intrauterine tissue manually instead of employing a high-frequency electric current. The device is intended to facilitate the treatment of intrauterine illnesses in a less invasive and efficient manner, giving patients the choice to maintain the organ and swiftly return to their regular lives.
Sep-2022: Medtronic together with CARE Hospitals Group, introduced the first gynecology (hysterectomy) procedure in the Asia Pacific leveraging the Hugo robotic-assisted surgery (RAS) system. To provide high-quality patient care at reasonable prices, investments in technology-enabled healthcare solutions are essential. High-quality equipment, like a robotic system, aids in accuracy improvement, shortens hospital stays, and speeds up patient recuperation.
Feb-2022: CooperCompanies signed an agreement to acquire Cook Medical's Reproductive Health Business, a company engaged in manufacturing minimally invasive medical devices for obstetrics, fertility, and gynecology markets. The acquisition added delivery devices to the former company's ObGyn portfolio and would expand its international fertility footprint.
Feb-2022: Laborie acquired Clinical Innovations for continuing to support moms, babies, and medical professionals all over the world by investing in and expanding Clinical Innovations' distinctive product line and specialist channels. The company's ability to serve the specific customer call point of obstetricians, gynecologists, neonatologists, and NICU and L&D nurses will be enhanced by Clinical Innovations' already strong and trusted relationships with physicians and nurses.
Dec-2021: CooperCompanies acquired Generate Life Sciences, a provider of donor sperm and egg for fertility cryopreservation service, fertility treatments, and newborn stem cell storage. With this acquisition, the company would be able to offer fertility clinics and OB/GYNs an even stronger service.
May-2021: CooperSurgical took over obp Medical Corporation, a company that focuses on developing and marketing diversified products comprising single-use vaginal speculums with combined LED illumination. The acquisition complemented CooperSurgical's portfolio of OB/GYN medical devices.
Mar-2021: CooperSurgical completed the acquisition of Safe Obstetric Systems, a company engaged in manufacturing medical devices, Fetal Pillow, an FDA-approved product used to raise the foetal head, making the birth easier and less traumatic for the mother and baby, after a fully dilated caesarean section. The acquisition is a perfect fit for CooperSurgical's mission of women's healthcare advancement.
Market Segments covered in the Report:
By Disease Type
By End User
By Surgical Approach
By Geography
Companies Profiled
Unique Offerings from KBV Research